Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
European Urology Focus|July 30, 2025
Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical TrialLars Björnebo, Andrea Discacciati, Ahmad Abbadi, et al.
European Urology Open Science|April 24, 2023
Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate CancerAnna Lantz, Per Nordlund, Ugo Falagario, et al.
BJUI Compass|September 26, 2024
Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancerFiorella L Roldan, Ugo Giovanni Falagario, Mats Olsson, et al.
Journal of the National Cancer Institute|May 8, 2024
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonistsLars Björnebo, Shirin Razdan, Andrea Discacciati, et al.
European Urology|December 2, 2023
Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old MenOla Bratt, Rebecka Arnsrud Godtman, Thomas Jiborn, et al.
European Urology Open Science|August 2, 2021
Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPROMartin Nyberg, Olof Akre, David Bock, et al.
International Journal of Molecular Sciences|July 27, 2022
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent DifferentiationFrancesca Sanguedolce, Magda Zanelli, Andrea Palicelli, et al.
Urology Journal|January 3, 2022
Development and External Validation of a Prediction Model to Identify Candidates for Prostate BiopsyVinayak G Wagaskar, Anna Lantz, Stanislaw Sobotka, et al.
BJU International|July 1, 2026
STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidanceNicola Giudici, Simone Scuderi, Thorgerdur Palsdottir, et al.
Cancer Reports (Hoboken, N.J.)|March 4, 2021
A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancerVinayak G Wagaskar, Stanislaw Sobotka, Parita Ratnani, et al.
Pageof 6